echemi logo
Product
  • Product
  • Supplier
  • Inquiry

    pd 650

    Echemi supplies various pd 650 news. It is easy to find the trends and top topics of pd 650 here.
    • Novartis paid $650 million for the overseas use of the anti-PD-1 drug tislezumab

      Time of Update: 2021-01-23
      Novartis and Baiji Shenzhou said they had evaluated Tislelizumab in 15 clinical trials involving more than 7,700 patients with various tumors, including NSCLC, HCC, esopausal squamous cell carcinoma, stomach cancer and nasopharyngeal cancer, and expected to file regulatory documents for the first time outside China in 2021.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.